S troke is one of the most frequent causes of death and disability worldwide. Although the pathogenesis and clinical significance of stroke recovery are clearly related to the functional cerebral lesions both in gray matter and white matter (WM), 1 the molecular mechanisms of gray matter and WM remodeling after stroke are not fully understood. New strategies to promote neurorestoration and to improve long-term neurological deficits after stroke are necessary beyond the hyperacute phase of ischemia.
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whether the ABCA1/ApoE/HDL signaling pathway mediates GW3965 treatment-induced neurorestoration after stroke.
Materials and Methods
For all in vivo studies, the use of animals and procedures were approved by the Institutional Animal Care and Use Committee of Henry Ford Health System. All animal groups, treatment, and their identity were blinded to the surgeon and the investigators who performed behavior tests, lesion volume and biochemical measurements, and immunostaining analysis. ) mice were used. The parent pairs of animals were generously provided by Dr Michael Hayden (University of British Columbia, Canada). Since female mice have an estrogen protective effect, in this study, we subjected male mice (middle-aged, 13-14 months) to permanent right distal middle cerebral artery occlusion (dMCAo) induced by transcranial ligation with a 10-0 nylon filament. The number of animals was calculated a priori by power calculation. Because dMCAo leads to a consistent lesion volume and low mortality, 9 animals per group were considered to reach 80% power at a significance level of <0.05, assuming 20% difference in both of mean and SD at the 95% confidence level and a 2-sided test.
Animals and Stroke Model
Specific
Experimental Groups
To investigate whether ABCA1/ApoE mediates GW3965-induced neurorestoration after stroke, ABCA1
fl/fl and ABCA1 −B/−B stroke mice were randomly divided into 4 groups by a nonteam member using the method of drawing different colored balls. Mice were gavaged starting 24 hours after dMCAo, with saline as vehicle control or GW3965 10 mg/kg (Sigma) daily for 14 days based on previous dosedependent study. 10 After 14 days of treatment, animals were randomly separated into 2 sets: one set of animals (total 24 mice, n=6/group) were used for Western blot (WB) and reverse transcriptase polymerase chain reaction assay; the other set of animals (total 36 mice, n=9/group) were used for behavioral testing, blood biochemistry, and lesion volume and immunostaining measurements.
To investigate the effect of HDL on GW3965-induced neurorestoration, ABCA1 −B/−B stroke mice were randomly assigned to 2 groups (total 18 mice, n=9/group) and intraventricularly infused with artificial cerebrospinal fluid (CSF; Tocris Bioscience) 100 μL as vehicle control or human plasma HDL3 (hHDL3; Cell Biolabs Inc) 25 μg in 100 μL artificial CSF by transplanting a micro-osmotic pump (D1002; Alzet) into the right lateral ventricle initiated at 24 hours after dMCAo for 14 days. All mice were euthanized 14 days after dMCAo.
Functional Test
The adhesive removal test, the most sensitive functional test for dMCAo, 11 was performed prior to dMCAo and at 1, 3, 7, and 14 days after dMCAo.
HDL, Total Cholesterol, and Triglyceride Measurement
Blood was collected from the tail vein 14 days after dMCAo, and the blood levels of HDL, total cholesterol, and triglyceride were measured using a CardioChek P·A analyzer and test strips (Polymer 285 Technology System). 
Lesion

Data and Statistical Analysis
Data are presented as mean±standard error. Two-way analysis of variance followed by Tukey post hoc test were performed for analysis: (1) 
Results
GW3965
Discussion
WM is composed of bundles of myelinated axons. WM remodeling (including axonal regeneration and remyelination) in the IBZ of cerebral infarcts is essential for long-term stroke recovery, and the process of remyelination is mediated by abundant OPCs located throughout the adult brain. 12, 13 Cholesterol is a major component of myelin, and axonal regeneration is in part dependent on local cholesterol utilization in regenerating neurons. 14, 15 Cholesterol is also an important component of neuronal membranes and participates in neuronal survival 16 and neuronal function, such as membrane trafficking, signal transduction, and neurotransmitter release. 15, 17, 18 Synaptic protein is formed from neuronal synapses, and cholesterol is essential lipid substrates for massive synaptogenesis in neurons. 18, 19 Synaptogenesis parallels functional recovery after cortical injury, including stroke. 20 HDL cholesterol plays an important role in WM remodeling and neurological functional recovery after brain injury. Almost all of HDL cholesterol in the central nervous system is derived from in situ biosynthesis mainly by ABCA1. 21, 22 Mutations in the human ABCA1 gene cause HDL deficiency syndrome, that is, Tangier disease, characterized by little or virtual absence of plasma HDL and prominent cholesterol deposition in tissues, cells, and prevalent atherosclerosis. 23, 24 In contrast, ABCA1 transgenic mice have a significant increase in cholesterol efflux in different tissues and marked elevation in HDL cholesterol levels. 8 Deficiency of ABCA1 also decreases ApoE level and impairs ApoE metabolism in brain.
3,5,25-27 Both ABCA1 and ApoE play a vital role in cholesterol homeostasis, neuronal repair, and synaptic plasticity.
28,29 ABCA1 −B/−B mice are generated by crossing loxP-flanked (floxed) ABCA1 mice with transgenic mice expressing Cre recombinant under the control of the neuronal and glial-specific nestin promoter. 25 This leads to an absence of ABCA1 in all nestin lineage cells (neural stem cells), including neurons and glia. These mice exhibit selective loss of brain ABCA1 and low level of HDL and ApoE in both brain tissue and CSF and reduced synapse and synaptic vesicle numbers in the brain. [25] [26] [27] Our previous study showed that there is no significant difference in both the WM density and the number of oligodendrocytes or OPCs in the brain of young (2-3 months) nonstroke ABCA1 −B/−B mice; however, ABCA1 −B/−B stroke mice exhibited more severe WM damage in the ischemic brain and worse functional outcome compared with ABCA1 fl/fl stroke mice 7 days after stroke. 30 In the present study, we found that the middle-aged ABCA1 −B/−B stroke mice exhibited decreased brain ABCA1/ApoE level, decreased WM remodeling and Syn-protein in both the contralateral and the ipsilateral ischemic brain, as well as decreased functional outcome compared with ABCA1 fl/fl stroke mice 14 days after dMCAo. Using PCN cultures, both ABCA1/Syn level and the neurite/axonal outgrowth significantly decreased in the ABCA1 −B/−B PCNs with or without OGD condition. These data indicate that ABCA1/ApoE play an important role in both the gray/WM remodeling after stroke.
Increase of HDL functionality may have important implications for treatment and prevention of cerebral WM damage after stroke. 31 The regulation of ABCA1/ApoE expression by LXRs is physiologically relevant in vivo because both ABCA1/ApoE and LXRs are expressed in neurons and glia in the brain. 28, [32] [33] [34] Activation of LXRs, which heterodimerizes with retinoid X receptors, induces the transcription of both ABCA1 and ApoE in vivo and in vitro. 35, 36 In addition, upregulation of ApoE via the LXR activation plays an important role in stroke recovery. 37 GW3965 crosses the blood-brain barrier and stimulates expression of many target genes, including ABCA1/ApoE. 6 GW3965 treatment raises HDL level in plasma, liver, and macrophages 10, 32, 38, 39 and increases expression of ABCA1/ApoE in the hippocampus and cerebral cortex and rescues hippocampus long-term synaptic plasticity in an Alzheimer's disease mouse model. 29 In the present study, we found that GW3965 treatment of ABCA1 fl/fl stroke mice significantly increased the levels of brain ABCA1/ApoE and blood HDL, increased gray matter/ -induced deficits both in vivo and in vitro. These data indicate that substrate (HDL) availability is a predominant factor for neurorestoration through ABCA1/ApoE cholesterol transporters after stroke.
Limitations
The risk of hepatic steatosis on pharmaceutical targeting of LXR may be a particularly serious consequence in humans. 40 T0901317, an LXRalpha agonist, induces liver steatosis through enhanced Srebp1-induced fatty acid syntheses and lipoprotein transcription. 41, 42 However, our present study shows that GW3965 treatment did not change blood triglyceride and total cholesterol. Consistent with our study, GW3965 raises HDL without inducing hepatic steatosis and hypertriglyceridemia 32, 38, 39 and do not affect hepatic insulin sensitivity 43 in rodents. Therefore, we should carefully choose LXRs for clinical use. In the present study, we are unable to provide evidence on which cell types, neurons, astrocytes, or oligodendrocytes play a primary role in mediating ABCA1 deficient-induced WM impairment or GW3965 treatment-induced WM remodeling, which is warranted to further studies.
Conclusions
We demonstrated, to our knowledge for the first time, that GW3965 treatment increases ABCA1/ApoE/HDL level, promotes gray matter/WM remodeling, and improves neurological functional outcome in ABCA1 fl/fl stroke mice 14 days after dMCAo. These beneficial responses were absent in ABCA1 −B/−B stroke mice; however, intracerebral infusion of hHDL3 attenuated ABCA1 deficient-induced deficits. Our data indicate that ABCA1/ApoE/HDL signaling pathway, at least partially, contributes to GW3965-induced neurorestoration after stroke.
